Bio-Techne (TECH): financials, SEC filings and peers
Bio-Techne (TECH) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Minneapolis, Minnesota.
It was founded in 1976 and joined the S&P 500 on August 30, 2021.
Its fiscal year ends in June, and its shares trade on the Nasdaq.
In its SEC filings it is classified as “Biological Products, (No Diagnostic Substances)”.
Bio-Techne at a glance
- Revenue (12 months)
- $1.2B
- Revenue growth
- -0.4%
- Operating margin
- 20.7%
- Net income (12 months)
- $182M
- Free cash flow (12 months)
- $263M
- Cash
- $265M
- Debt
- $200M
- Diluted EPS (12 months)
- $1.15
Twelve months to June 30, 2026, from the 10-K filed August 24, 2026.
Latest twelve months
Over the twelve months to June 30, 2026, Bio-Techne reported revenue of $1.2 billion, about the same as a year earlier (-0.4%).
Its operating margin was 20.7%, up 12.3 percentage points from a year earlier: for every $100 of sales, about $21 was left as operating profit.
Net income was $182 million (15.0% of revenue), 147.8% higher than a year earlier.
Operating cash flow was $292 million and capital spending $29 million, leaving free cash flow of $263 million (21.7% of revenue).
At the end of the period it held $265 million in cash and $200 million in debt, a net cash position of $65 million.
The diluted share count fell 107.0% in a year, typically the result of buybacks.
Five-year trend
- Revenue went from $931 million in fiscal 2021 to $1.2 billion in fiscal 2026, about 5.5% a year.
- Operating margin narrowed from 25.5% to 20.7% over the same years.
- Free cash flow was positive in each of the last 6 fiscal years.
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.2B | $1.2B | $1.2B |
| Revenue growth | 18.7% | 2.8% | 2.0% | 5.2% | -0.4% |
| Operating margin | 26.8% | 26.3% | 17.8% | 8.4% | 20.7% |
| Net income | $272M | $285M | $168M | $73M | $182M |
| Free cash flow | $280M | $216M | $236M | $257M | $263M |
| Diluted EPS | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
Fiscal years as reported in Bio-Techne’s 10-K filings. Free cash flow is operating cash flow minus capital spending.
Recent SEC filings
- 8-K filed September 23, 2026 — Shareholder vote results; Regulation FD disclosure
- 8-K filed September 14, 2026 — Other event
- 10-K filed August 24, 2026 — annual report
- 8-K filed August 12, 2026 — Earnings results; Other event
- 8-K filed June 26, 2026 — Material agreement; Executive or director change
- 8-K filed June 25, 2026 — Regulation FD disclosure
- 10-Q filed May 6, 2026 — quarterly report
- 8-K filed May 6, 2026 — Earnings results; Other event
Companies like Bio-Techne
Other S&P 500 companies in Life Sciences Tools & Services:
- AAgilent TechnologiesSanta Clara, California
- CRLCharles River LaboratoriesWilmington, Massachusetts
- DHRDanaher CorporationWashington, D.C.
- ILMNIllumina, Inc.San Diego, California
- IQVIQVIADurham, North Carolina
- MTDMettler ToledoColumbus, Ohio
- TMOThermo Fisher ScientificWaltham, Massachusetts
- WATWaters CorporationMilford, Massachusetts
More from Health Care
Questions about Bio-Techne
Is Bio-Techne's revenue growing?
No. Revenue for the twelve months to June 30, 2026 was $1.2 billion, down 0.4% from a year earlier, according to its SEC filings.
Is Bio-Techne profitable?
Yes. It earned $182 million in net income over the twelve months to June 30, 2026, a net margin of 15.0%.
Does Bio-Techne have more cash or more debt?
At June 30, 2026 it had $265 million in cash and $200 million in debt, so more cash than debt.
When did Bio-Techne last file financial results?
Its latest annual report (10-K) was filed with the SEC on August 24, 2026.
Which companies are similar to Bio-Techne?
In the S&P 500, Bio-Techne is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Danaher Corporation (DHR), Illumina, Inc. (ILMN), IQVIA (IQV) are in the same group.
Understand the numbers
Source: Bio-Techne’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.